Rigel steps back from sNDA filing plans for bleeding disorder drug; NMD gives first look into myasthenia gravis program
In June, Rigel reported a Phase III fail for its only approved drug, fostamatinib, in warm autoimmune hemolytic anemia, or wAIHA for short, an autoimmune …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
